earnings
confidence high
sentiment neutral
materiality 0.75
Lifecore raises $24.3M via stock sale; Q1 net loss widens to $16.2M, reaffirms FY25 guidance
LIFECORE BIOMEDICAL, INC. DE
2025-Q1 EPS
reported -$0.53
vs consensus -$0.15
▼ miss
(-246.4%)
- Sold 5,928,775 shares at $4.10 for gross proceeds of $24.3M to investors including Legion Partners, Greenhaven, Wynnefield, 325 Capital.
- Q1 FY25 revenue $24.7M (flat YoY); net loss $16.2M ($0.53 per share) vs $10.8M loss prior year.
- Adjusted EBITDA $(1.8)M in line with prior year $(2.0)M; FY25 guidance reaffirmed: rev $126.5-130M, Adj EBITDA $19-21M.
- Installed 5-head isolator filler doubling capacity to $300M revenue potential; signed four new customers including Lindy Biosciences.
- Regained Nasdaq compliance; added two sales reps; plans Investor Day in November to detail medium-term targets.